http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Butov, (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Dmytro Butov ),( Yurii Feshchenko ),( Mykhailo Kuzhko ),( Mykola Gumenuik ),( Kateryna Yurko ),( Alina Grygorova ),( Anton Tkachenko ),( Natalia Nekrasova ),( Tetiana Tlustova ),( Vasyl Kikinchuk ) 대한결핵 및 호흡기학회 2020 Tuberculosis and Respiratory Diseases Vol.83 No.1
Background: The aim of this study was to investigate the effectiveness of intravenous isoniazid (H) and ethambutol (E) administered in patients with new sputum positive drug-susceptible pulmonary tuberculosis (TB) with tuberculous meningoencephalitis (TM) and human immunodeficiency virus (HIV) co-infection in the intensive phase of treatment. Methods: Fifty-four patients with TB/TM and HIV co-infection were enrolled for this study. Group 1 comprised of 23 patients treated with E and H intravenously, while rifampicin and pyrazinamide were prescribed orally. Group 2 consisted of 31 patients treated with the first-line anti-TB drugs orally. The concentrations of H and E in blood serum were detected using a chromatographic method. Results: A significant improvement in the clinical symptoms and X-ray signs in patients treated intravenously with H and E was observed and compared to group 2. The sputum Mycobacterium tuberculosis positivity was observed during the second month of the treatment in 25.0% of patients from group 1 and 76.1% of the patients from the control group (p=0.003). In addition, nine patients (39.1%) died up to 6 months when H and E were prescribed intravenously compared with 22 (70.9%) in group 2 (p=0.023). Conclusion: In TB/TM with HIV, the intravenous H and E treatment was more effective than oral H and E treatment at 2 months of intensive treatment in sputum conversion as well as in clinical improvement, accompanied by significantly higher mean serum concentrations. In addition, the mortality rate was lower in intravenous H and E treatment compared to oral treatment.
-
( Aldar S Bourinbaiar1 ),( Marina V Mezentseva ),( Dmitry A Butov ),( Peter S Nyasulu ),( Yuri V Efremenko ),( Vichai Jirathitikal ),( Vladimir V Mishchenko ),( Galyna A Kutsyna ) 대한결핵 및 호흡기학회 2012 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.114 No.-
Tuberculosis is typically caused by Mycobacterium tuberculosis, a symbiotic bacterium found in one third of the world population. There any many factors triggering overt clinical disease in a small proportion of humans. In our view the major role in this process is played by host`s immune response, especially self-directed, destructive inflammation. Conventional che-motherapy produces bactericidal or bacteriostatic effects, but immunopathological changes can be corrected by immunotherapy only. Various attempts have been made to find the optimal immune intervention. Some have shown promising effect, but many have failed. It is commonly held that the field started in 1890-the year Robert Koch announced his tuberculin therapy. In the P?n Ts`ao Kang Mu - classical Chinese materia medica published during Ming dynasty - Li Shi Chen (1518-1593) recom-mended as a remedy for hemoptysis to collect from the sputum "…blood lumps, roast them till they are black, and take then them as a powder." In retrospect, this is perhaps the earliest recorded reference relating to immunotherapy of TB with heat-kil-led mycobacteria. Modern science is obviously geared toward more palatable approach, but without hindsight from often dis-dained empirical evidence no progress can be made. Clinically tested immunotherapies for tuberculosis recently developed by us will be presented in this talk.
ScienceON
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
